The manual visual inspection program is inadequate to identify turbidity, precipitate, and particulates in the NT -501 combination product.
Inspection Record
Neurotech Pharmaceuticals, Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Inadequate quality oversight to assure that the NT -501 combination product has the identity, strength, quality, and purity it purports or is represented to possess.
Management with executive responsibility has not ensured that an adequate and effective quality system has been established.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.